Clinical trials: Uncomplicated Plasmodium Falciparum Malaria
Malaria, Falciparum
Azithromycin Plus Chloroquine Versus Atovaquone-Proguanil For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In South America
The primary objective is to confirm the hypothesis that azithromycin plus chloroquine is non-inferior to atovaquone-proguanil for the treatment of symptomatic, uncomplicated malaria due to P. falciparum.
- Trial name
- NCT00084227
- Testing
- Azithromycin/Chloroquine, Atovaquone/Proguanil
- Volunteers
- 244 people
- Sponsor
- Pfizer
Malaria
Randomised Trial of 3 Artemisinin Combination Therapy for Malaria in Pregnancy
This is a randomised, open label trial, comparing standard dose of dihydroartemisinin-piperaquine (DP) with standard fixed artesunate-mefloquine regimen (MAS3) and with a longer regimen of artemether-lumefantrine (ALN+) in the…
- Trial name
- DMA (NCT01054248)
- Testing
- dihydroartemisinin-piperaquine, Artesunate-mefloquine, arthemeter-lumefantrin
- Where
- Thailand
- Volunteers
- 511 people
- Sponsor
- University of Oxford
Uncomplicated Falciparum Malaria, Artemisinin-resistant
Arterolane-PQP Versus DHA-PQP in Uncomplicated Falciparum Malaria in Eastern Myanmar
Emerging resistance to artemisinins and their partner drugs severely threatens the treatment of falciparum malaria in Myanmar with artemisinin combination therapies.
- Trial name
- NCT02461186
- Testing
- Arterolane maleate-piperaquine phosphate (Synriam), Dihydroartemisinin-piperaquine phosphate (Duocotexin)
- Sponsor
- University of Oxford
Plasmodium Falciparum, Malaria, Falciparum
Safety, Tolerability, Pharmacokinetics and Efficacy of ARCO
Phase IV, single center, 2 arms randomized controlled, open label study. Study will be conducted over a period of 42 days to determine the safety, tolerability, pharmacokinetics and efficacy of ARCO.
- Trial name
- NCT01930331
- Testing
- artemisinin/naphthoquine, dihydroartemisinin/piperaquine phosphate
- Where
- Tanzania
- Volunteers
- 60 people
- Sponsor
- Ifakara Health Institute
Malaria
PALUREA: Severe Imported Malaria in Adults
Plasmodium falciparum malaria remains a major public health problem in endemic areas, with approximately 2 million deaths each year, especially in tropical African countries.
- Trial name
- PALUREA (NCT00372684)
- Testing
- with severe malaria hospitalized in ICU, with uncomplicated malaria
- Where
- France
- Volunteers
- 302 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Uncomplicated Plasmodium Falciparum Malaria
Triple Artemisinin-based Combination Therapy for Delaying Drug Resistance Development - a Randomized Clinical Trial
Background: Artemisinin resistance has emerged in parts of Southeast Asia, and there are reports in Africa of reduced susceptibility of Plasmodium falciparum parasites against artemisinin-based combination therapy (ACT).
- Trial name
- 3ACT (NCT05764746)
- Testing
- Artemether-lumefantrine and Amodiaquine Drug Combination, Artemether-lumefantrine then Artesunate amodiaquine, Artemether-lumefantrine
- Where
- 2 sites in Tanzania
- Volunteers
- 384 people
- Sponsor
- Muhimbili University of Health and Allied Sciences
Malaria
Harmonized AS/MQ Efficacy Study - Thailand
The purposes of this study is to determine parasitological clearance rates by microscopy for the 72-hour period after first artesunate dose in subjects with uncomplicated P. falciparum malaria.
- Trial name
- NCT02052323
- Testing
- Artesunate/mefloquine (AS/MQ)
- Where
- Thailand
- Volunteers
- 48 people
- Sponsor
- Armed Forces Research Institute of Medical Sciences, Thailand
Malaria
Efficacy of Artesunate-amodiaquine and Artemether-lumefantrine for Uncomplicated Malaria in South Kivu, DR Congo
This will be an open-randomised non-inferiority study to test the hypothesis that the risk of recurrent parasitaemia after 42 days is not worse in the group receiving the Artesunate-Amodiaquine (ASAQ) regimen than in the group…
- Trial name
- NCT02741024
- Testing
- Amodiaquine-Artesunate (ASAQ), Artemether-Lumefantrine (AL)
- Volunteers
- 288 people
- Sponsor
- Medecins Sans Frontieres, Netherlands
Malaria, Falciparum
Artemisinin-based Combination Therapy for Treatment of Plasmodium Falciparum Malaria in North Sumatera, Indonesia
This is a prospective, open label, randomised controlled trial to assess the safety and efficacy of dihydroartemisinin-piperaquine and artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum…
- Trial name
- NCT02325180
- Testing
- Dihydroartemisinin-Piperaquine, Artemether-lumefantrine
- Where
- 3 sites in Indonesia
- Volunteers
- 338 people
- Sponsor
- London School of Hygiene and Tropical Medicine
Plasmodium Falciparum, Malaria
Efficacy of Artesunate-amodiaquine and Artemether-lumefantrine for Treatment of Plasmodium Falciparum Malaria in Liberia
To assess the efficacy of both first-line antimalarial medications used for the treatment of uncomplicated Plasmodium falciparum malaria infections in two geographic regions in Liberia.
- Conditions
- Plasmodium Falciparum, Malaria, Uncomplicated Malaria
- Trial name
- NCT06300970
- Testing
- Amodiaquine-artesunate (ASAQ), Artemether+Lumefantrine (AL)
- Where
- 2 sites in Liberia
- Volunteers
- 352 people
- Sponsor
- Centers for Disease Control and Prevention
Uncomplicated Falciparum Malaria
Azithromycin Combination Therapy for the Treatment of Uncomplicated Falciparum Malaria in Bangladesh
The purpose of this study is to investigate the efficacy of azithromycin combination therapy with artesunate for the treatment of uncomplicated falciparum malaria in Bangladesh.
- Trial name
- NCT00356005
- Testing
- azithromycin plus artesunate, Artesunate
- Where
- Bangladesh
- Volunteers
- 228 people
- Sponsor
- Medical University of Vienna
Uncomplicated Falciparum Malaria
Efficacy and Safety of ASAQ and PD for the Treatment of Uncomplicated Falciparum Malaria in Mainland Tanzania
The World Health Organization recommends regular surveillance of antimalarial efficacy to monitor the performance of different drugs.
- Trial name
- GF-TES-2017 (NCT03431714)
- Testing
- Artesunate amodiaquine
- Where
- Tanzania
- Volunteers
- 333 people
- Sponsor
- National Institute for Medical Research, Tanzania
Malaria, Falciparum
Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine For The Treatment Of Uncomplicated, Symptomatic Falciparum Malaria In Southeast Asia
The primary objective is to confirm the hypothesis that azithromycin (optimal dose once daily for three days) plus chloroquine is non-inferior to sulfadoxine-pyrimethamine plus chloroquine for the treatment of uncomplicated…
- Trial name
- NCT00084240
- Testing
- Azithromycin/Chloroquine, Sulfadoxine-Pyrimethamine/Chloroquine
- Volunteers
- 32 people
- Sponsor
- Pfizer
Malaria, Falciparum, Malaria, Vivax
Efficacy, Tolerability, PK of OZ439 in Adults With Acute, Uncomplicated P.Falciparum or Vivax Malaria Mono-infection
A Phase IIa Exploratory, Open label, Single Dose Regimen, Multiple Dose Testing Clinical Study to Assess the Preliminary Efficacy, Tolerability and Pharmacokinetics of OZ439 in adult patients with acute, uncomplicated Plasmodium…
- Trial name
- NCT01213966
- Testing
- OZ439
- Volunteers
- 82 people
- Sponsor
- Medicines for Malaria Venture
Plasmodium Falciparum Malaria
Phase II Dose-ranging Study of Pyronaridine/Artesunate in Adults Patients With Plasmodium Falciparum Malaria
The primary trial objective is to determine the clinically effective dose of orally administered pyronaridine/artesunate (Pyramax®, PA) with a 3:1 ratio to treat adults with acute, symptomatic, uncomplicated P.
- Trial name
- NCT01594931
- Testing
- pyronaridine/artesunate
- Where
- 6 sites in Cambodia, Indonesia and 4 more
- Volunteers
- 477 people
- Sponsor
- Medicines for Malaria Venture
Malaria
Safety and Efficacy of Recommended Antimalarial in the Democratic Republic of the Congo
Despite all efforts, malaria remains a public health concern, in particular in the Democratic Republic of the Congo (DRC). The National Malaria Control program recommends artemisinin-based combination treatments (ACTs), in…
- Trial name
- TET2020 (NCT04618523)
- Testing
- Artesunate-amodiaquine, Artemether-lumefantrine
- Where
- 6 sites in Democratic Republic of the Congo
- Volunteers
- 1,117 people
- Sponsor
- Ministry of Public Health, Democratic Republic of the Congo
Malaria, Falciparum
Efficacy Study of Amodiaquine-Artesunate and Artemether-Lumefantrine for the Treatment of Uncomplicated Malaria
In the Democratic Republic of Congo (DRC), malaria is an important cause of morbidity and mortality. It is estimated that malaria is responsible for 30% of admissions to hospital averaged throughout the country and for 25-30%…
- Trial name
- NCT01567423
- Testing
- ASAQ Winthrop® Sanofi Aventis, Coartem®, Novartis
- Where
- Democratic Republic of the Congo
- Volunteers
- 301 people
- Sponsor
- Epicentre
Malaria, Falciparum
Assessing the Efficacy of Four Drug Combinations as the Next First-line Therapy for Uncomplicated Malaria in Malawi
Sulfadoxine-pyrimethamine (SP) is the current first-line treatment for uncomplicated malaria in Malawi. The malaria parasite P. falciparum has developed resistance to this drug so that the drug is much less effective than in…
- Trial name
- NCT00164710
- Testing
- sulfadoxine-pyrimethamine, amodiaquine plus sulfadoxine-pyrimethamine, amodiaquine plus artesunate
- Where
- 3 sites in Malawi
- Volunteers
- 365 people
- Sponsor
- Centers for Disease Control and Prevention
Malaria
Effectiveness of Artemether-Lumefantrine for Malaria Treatment of Children at Community Level in Tanzania
The purpose of this clinical trial is to assess the effectiveness of artemether-lumefantrine (Coartem®) treatment provided by community health workers against uncomplicated malaria in children under 5 years of age in Kibaha…
- Trial name
- C3 (NCT00454961)
- Testing
- artemether-lumefantrine
- Where
- Tanzania
- Volunteers
- 200 people
- Sponsor
- Karolinska University Hospital
Uncomplicated P. Falciparum Malaria
SPK Study in Afghanistan
In Afghanistan, studies over the past 15 years have shown a high degree of Plasmodium falciparum resistance to chloroquine. In 2003 the high failure rate of chloroquine against falciparum malaria led the national malaria…
- Trial name
- NCT01707199
- Testing
- Artesunate + Sulphadoxine-pyrimethamine
- Where
- Afghanistan
- Volunteers
- 83 people
- Sponsor
- University of Oxford